ImmunoTheragnostics Overview

  • Founded
  • 2005
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $1.5M
Latest Deal Amount

ImmunoTheragnostics General Information


Developer of therapeutic and prognostic equipment designed for women. The company engages in research, development and commercialization of exosome-based clinical diagnostic arrays for cardiovascular diseases and cancer, enabling women to diagnose cell deterioration.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Other Industries
Therapeutic Devices
Karas Diagnostic Company
Primary Office
  • 201 East Jefferson Street
  • Suite 315
  • Louisville, KY 40202
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmunoTheragnostics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 01-Dec-2008 $1.5M 00000 00.00 Completed Startup
1. Early Stage VC (Series A) 00000 00000 Completed Startup
To view ImmunoTheragnostics’s complete valuation and funding history, request access »

ImmunoTheragnostics Executive Team (1)

Name Title Board Seat Contact Info
Douglas Taylor Chief Executive Officer & President
To view ImmunoTheragnostics’s complete executive team members history, request access »

ImmunoTheragnostics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Mammoth View (KSTC) Venture Capital Minority 000 0000 000000 0
MetaCyte Business Lab Accelerator/Incubator Minority 000 0000 000000 0
To view ImmunoTheragnostics’s complete investors history, request access »